Skip to main content
. Author manuscript; available in PMC: 2015 Jul 28.
Published in final edited form as: J Cancer Ther. 2011 Mar 31;2(1):22–39. doi: 10.4236/jct.2011.21004

Figure 4.

Figure 4

Influence of covalent bonding anti-HER2/neu monoclonal immunoglobulin on the cytotoxic anti-neoplastic potency of epirubicin against chemotherapeutic-resistant SKBr-3 mammary carcinoma. Legend: (◆) covalent epirubicin-(C13-imino)-[anti-HER2/neu] immunochemotherapeutic, and (∎) epirubicin chemotherapeutic. Monolayer populations of SKBr-3 mammary carcinoma were incubated with epirubicin immunochemotherapeutic for 72-hours and cytotoxicity measured as a function of cell MTT vitality relative to matched negative reference controls.